AlzeCure gets late-breaking abstract on pain project TrkA-NAM accepted for presentation

AlzeCure gets late-breaking abstract on pain project TrkA-NAM accepted for presentation

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that it has received approval to present an abstract on its preclinical project TrkA-NAM for osteoarthritic pain and other severe pain disorders at the IASP 2021 World Congress on Pain, which this year will be held completely digitally on June 9-11 and June 16-18.

The late-breaking abstract, titled Negative Allosteric Modulators of TrkA for the Treatment of Pain, will be presented at the global pain conference IASP 2021 World Congress on Pain by Dr. Pontus Forsell, Head of Discovery at AlzeCure and project leader of the TrkA-NAM project. The other authors include Dr. Gunnar Nordvall, Head of Chemistry at AlzeCure, Dr. Magnus Halldin, Head of DMPK & Safety Assessment at AlzeCure, and Dr. Johan Sandin, CSO at AlzeCure.
 
Results from the lead optimization program show that the NGF/TrkA pathway is a well validated and a promising alternative for new analgesics without the side effects and dependency issues observed with opioids. Identification of selective and potent small molecule TrkA-NAM’s could potentially avoid some of the side effects observed for anti-NGF antibodies due to a more selective mechanism of action, while retaining the analgesic efficacy. We have in our lead optimization program identified very potent and selective TrkA-NAM’s and demonstrated pain relief in vivo.
 
“I am very pleased that we receive an approval for a second abstract from our very exciting Painless platform at this prestigious conference. This is a clear validation of our R&D platform and strengthens our conviction that we are right in our research and our projects. The data we have for TrkA-NAM in pain disordes are promising, and we look forward to present it", said Martin Jönsson, CEO of AlzeCure Pharma AB.
 
The abstract and the poster will be available on AlzeCure’s website after the presentation (https://www.alzecurepharma.se/en/publications).
 

For more information, please contact

Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com

About AlzeCure Pharma AB (publ)

AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer’s disease and pain – indications for which currently available treatment is extremely limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
 
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows multiple indications, including Alzheimer’s disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson’s disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer’s disease and comprises two candidates. Painless is the company’s research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure® aims to pursue its own projects through preclinical research and development to early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
 
FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se, is the company’s Certified Adviser. For more information, please visit www.alzecurepharma.se.

About TrkA-NAM
The TrkA-NAM project, which is in the research phase, is aimed at treatment of pain and has strong preclinical and clinical validation.
 
For the TrkA-NAM drug project, we have leveraged our knowledge concerning the underlying biology for the NeuroRestore platform in order to develop new compounds that focus on providing pain relief in conditions associated with severe pain.
 
The goal of the project is to develop a small-molecule TrkA-negative allosteric modulator that can reduce movement-induced and spontaneous pain in patients with painful conditions such as osteoarthritis. The global osteoarthritis market is expected to reach USD 11.0 billion by 2025, from USD 7.3 billion in 2020. Growth in this market is driven by factors such as the increasing occurrence of osteoarthritis, the growing aging population, and an increase in the number of sports injuries. Over 240 million people worldwide suffer from painful and activity-limiting osteoarthritis of the hip or knee. Many patients experience insufficient pain relief or side effects with current treatment, which today usually consist of NSAIDs or opiates and there is a great need for more effective and better tolerated drugs in this field.